Le point de vue du biologiste sur la pharmacogénétique dans le cancer colorectal

摘要: Several drugs have been developed and demonstrated similar efficacy in colorectal cancer treatment therefore with choice, time comes for decision. The biologist will to provide the tools allowing clarify this choice. Among available, those of pharmacogenetics pharmacogenomics appear most promising recent examples allow illustrate their clinical interest. anti-cancer agents presents a characteristic, which requires hold into account genetic variations not only host cells but also tumor cells. conclusive one is that prediction severe neutropenia induced by irinotecan among patients homozygous * 28 allele UGT1A1 enzyme conjugates SN38 active compound irinotecan, other presence KRAS mutated cell predict resistance anti EGFR antibodies metastatic cancer.